title: Three-year survey of amikacin use and aminoglycoside resistance in a general hospital in Belgium.
abstract: The aim of the study was to evaluate the effect of intensive use of amikacin on the resistance levels to amikacin, gentamicin, tobramycin, netilmicin and dibekacin. The base-line resistance in the preamikacin phase (three months of amikacin use less than 1%; 676 isolates) was 1.0% for amikacin, 11.4% for gentamicin, 8.0% tobramycin, 6.2% for netilmicin and 8.3% for dibekacin. During the amikacin phase (36 months of average amikacin use of 89%; 6048 isolates) there was no significant change in aminoglycoside resistance except for dibekacin (from 8.3% to 10.9%, 0.05 greater than p greater than 0.02). Isolated amikacin resistance was not observed.
mesh_terms: D000583:Amikacin / Q000494:pharmacology* / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D001530:Belgium; D003982:Dibekacin / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D004363:Drug Utilization; D005839:Gentamicins / Q000494:pharmacology; D006769:Hospitals, General; D006801:Humans; D009428:Netilmicin / Q000494:pharmacology; D014031:Tobramycin / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D005839:Gentamicins; D003982:Dibekacin; D009428:Netilmicin; D000583:Amikacin; D014031:Tobramycin